文献速递临床试验与 GCP基础与转化研究

酵母甘露聚糖补充对成人排便频率影响的随机对照试验

Efficacy of yeast mannan supplementation on increasing stool frequency in adults: a randomized controlled trial.
PubMed 文献 · Trials · 2026-07-28

本研究为一项为期6周的双盲平行随机试验,计划纳入60名成人,比较每日补充12克酵母甘露聚糖(含甘露寡糖和甘露蛋白的酿酒酵母细胞壁组分)与对照(麦芽糊精和酵母蛋白)对日均排便频率的影响。次要目标包括评估胃肠道耐受性、生活质量、全肠道传输时间、粪便微生物组成及微生物代谢物水平。假设酵母甘露聚糖可增加排便频率、耐受性良好并特异性调节肠道菌群。

要点

  • 每日补充12克酵母甘露聚糖可能增加成人日均排便频率。
  • 次要结局包括胃肠道耐受性、全肠道传输时间和粪便微生物组成。
  • 采用双盲随机对照设计,干预4周,基线期2周。

核心结论

  • 假设酵母甘露聚糖可增加成人日均排便频率,且耐受性良好并调节肠道菌群。

研究设计与样本

  • 6周双盲、平行、随机对照试验,纳入60名成人,干预组每日补充12克酵母甘露聚糖,对照组补充麦芽糊精和酵母蛋白。

关键数值与推荐

  • 主要结局为组间基线至干预后日均排便频率变化比较。
  • 全肠道传输时间采用80%不透X线标记物回收法估计。
  • 粪便微生物组采用全宏基因组测序,使用metaphlan4、Braken等工具分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Yeast mannans are microbial-available substrates that may improve laxation and specifically modulate gut microbiota composition. The aim of this study is to determine the effect of yeast mannan supplementation on stool frequency in adults. Secondary aims will assess gastrointestinal tolerance and quality of life, whole gut transit time, fecal microbiota composition, and fecal and urinary levels of microbial-generated metabolites. METHODS: A 6-week, double-blinded, parallel, randomized trial will evaluate the effect of 12 g of yeast mannan (Saccharomyces cerevisiae cell wall fraction containing mannan-oligosaccharides and mannoproteins) or control (maltodextrin and yeast protein) supplementation on mean daily stool frequency in adults (n = 60). Participants will complete a daily survey of stool frequency, gastrointestinal symptoms, and quality of life, any adverse events, and compliance with supplement intake during the 2-week baseline and 4-week intervention periods; gastrointestinal tolerance will be assessed weekly. Capsules containing radiopaque markers will be administered, and all stools will be collected during the last 3 days of baseline and intervention. Whole gut transit time will be estimated using the 80% recovery of radiopaque markers method. Per period, 24-h urine will be collected, and metabolomics will be determined by LC-MS/MS. For the primary outcome, change from baseline daily stool frequency between groups will be compared, and between-group comparisons of secondary outcomes using appropriate generalized linear regression models, and for those outcomes with repeated measures, linear mixed effect models. Fecal microbiome using whole metagenome sequencing data will be processed using metaphlan4, Braken, or another tool appropriate for estimating the relative abundance of microbial species. Additional analysis using tools such as humann3 will enable functional assignment of reads. Resulting relative abundance and normalized functional data will be further analyzed using a combination of tools in R software, including phyloseq and vegan packages. DISCUSSION: In accordance with our pilot open-label study, the hypothesis is that yeast mannans will increase daily stool frequency, be highly tolerable, and demonstrate specific modulation of the microbiota, supporting its prebiotic properties. Additionally, yeast mannan supplementation may decrease whole gut transit time and mitigate the microbial production of inflammatory microbial-generated metabolites. TRIAL REGISTRATION: NCT ID NCT06911177. Registered on 04 April 2025.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Moreno ML, Taft DH, Tompkins TA, et al. Efficacy of yeast mannan supplementation on increasing stool frequency in adults: a randomized controlled trial. Trials. 2026. PMID: 42919413. doi:10.1186/s13063-026-09921-y

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。